Steven Cohen Akero Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,663,339 shares of AKRO stock, worth $90.2 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

1,663,339

Previous 2,710,929 38.64%

Holding current value

$90.2 Million

Previous $145 Million 45.4%

% of portfolio

0.15%

Previous 0.32%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$42.18 - $54.33 $44.2 Million - $56.9 Million	-1,047,590 Reduced 38.64%	1,663,339 $79 Million
Q2 2025 Aug 14, 2025	BUY	$34.04 - $56.28 $75 Million - $124 Million	2,202,589 Added 433.29%	2,710,929 $145 Million
Q1 2025 May 15, 2025	SELL	$21.87 - $57.56 $8.56 Million - $22.5 Million	-391,340 Reduced 43.5%	508,340 $20.6 Million
Q4 2024 Feb 14, 2025	SELL	$26.75 - $35.28 $10.8 Million - $14.2 Million	-403,643 Reduced 30.97%	899,680 $25 Million
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $28 Million - $38.2 Million	1,303,323 New	1,303,323 $37.4 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $6.31 Million - $11.1 Million	-355,199 Reduced 55.13%	289,106 $7.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $6.89 Million - $30.5 Million	605,705 Added 1569.18%	644,305 $15 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $1.59 Million - $2.02 Million	38,600 New	38,600 $1.95 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $3.62 Million - $6.8 Million	453,000 Added 24.53%	2,300,000 $21.7 Million
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $1.15 Million - $1.97 Million	88,499 Added 5.03%	1,847,000 $26.2 Million
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $7.16 Million - $9.45 Million	360,101 Added 25.75%	1,758,501 $37.2 Million
Q3 2021 Nov 15, 2021	BUY	$18.65 - $25.46 $3.85 Million - $5.26 Million	206,700 Added 17.34%	1,398,400 $31.3 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $17 Million - $22.2 Million	685,203 Added 135.28%	1,191,700 $29.6 Million
Q1 2021 May 17, 2021	SELL	$24.04 - $34.19 $4.77 Million - $6.79 Million	-198,503 Reduced 28.16%	506,497 $14.7 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $14.1 Million - $16.8 Million	561,861 Added 392.53%	705,000 $18.2 Million
Q3 2020 Nov 16, 2020	SELL	$30.79 - $39.92 $9.3 Million - $12.1 Million	-301,893 Reduced 67.84%	143,139 $4.41 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $5.39 Million - $7.5 Million	-280,213 Reduced 38.64%	445,032 $11.1 Million
Q1 2020 May 15, 2020	BUY	$12.8 - $27.05 $6.39 Million - $13.5 Million	498,945 Added 220.48%	725,245 $15.4 Million
Q4 2019 Feb 14, 2020	BUY	$17.37 - $27.27 $2.08 Million - $3.26 Million	119,600 Added 112.09%	226,300 $5.02 Million
Q3 2019 Nov 15, 2019	BUY	$16.89 - $29.88 $1.3 Million - $2.29 Million	76,700 Added 255.67%	106,700 $2.43 Million
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $542,400 - $594,900	30,000 New	30,000 $575,000

Others Institutions Holding AKRO

# of Institutions

302

Shares Held

91.5M

Call Options Held

1.05M

Put Options Held

388K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account